

ASX Release

28 June 2018 | CannPal Animal Therapeutics Limited ACN: 612 791 518 | ASX:CP1

CannPal Receives Funding for Research Collaboration with CSIRO

Key Highlights

- CannPal has entered into a research agreement with CSIRO, as part of the national science organisation's CSIRO Kick-Start initiative for eligible Australian SMEs (Small to Medium Enterprises)
- Under the initiative, CannPal will receive dollar-matched funding to contribute towards an eligible collaborative research project with CSIRO researchers
- Together, CannPal and CSIRO will undertake research into the use of food production technologies to enhance the delivery of CannPal's cannabis-derived therapeutic formulations in animals

28 June 2018: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce that it has entered into a research agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) under the *CSIRO Kick-Start* initiative.

CSIRO Kick-Start was launched in April 2017, providing innovative Australian start-ups and SMEs with funding support and access to CSIRO's research expertise and facilities. The program offers eligible businesses access to dollar-matched funding vouchers of between AUD\$10,000-\$50,000 to undertake the following research activities with CSIRO:

- Research into a new idea with commercial potential,
- Development of a novel or improved product or process, or
- The testing of a novel product or material developed by the business.

Under the initiative CSIRO and CannPal will undertake initial research into formulation work. CannPal intends to further develop new and existing delivery systems to create proprietary formulations of the Company's therapeutic products, which CannPal management believes could provide a significant competitive advantage.

CannPal is developing a range of cannabis based therapeutic products targeting companion animals, with a focus on DermaCann, a nutraceutical targeting canine skin health, and CPAT-01 in development as a veterinary medicine for pain in dogs.

CannPal's Founder and Managing Director Layton Mills:

"We are very pleased to have received this funding voucher as part of our research agreement with the CSIRO. Our vision is to be a global leader in cannabinoid-derived therapeutics, and through this research agreement, we're confident that we can develop added value that can significantly advance the development of our therapeutic platform"











ASX Release

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

To learn more please visit: www.cannpal.com

About CSIRO

CSIRO is Australia's national science agency and one of the largest and most diverse research agencies in the world. We employ a team of more than 5,000 world-class scientists, engineers, technologists and economists to deliver solutions for some of the world's most challenging problems and make a difference to the economy, society and the environment.

CSIRO Kick-Start is an initiative offered through CSIRO's SME Connect team. SME Connect provides a single point of contact for Australian SMEs to engage with CSIRO, universities and public research organisations. The team works with SMEs to identify opportunities for research to benefit their business, connects them to the best Australian researchers, and currently facilitates access to research project funding.

"This research project was made possible through the CSIRO Kick-start program, providing CannPal with access to our research expertise and capabilities and dollar-matched funding to undertake the research project. CSIRO Kick-start is designed specifically to support the growth of start-ups and small businesses that are on their way to becoming Australian success stories."

www.csiro.au/SMEconnect

END

For further information, please contact:

CannPal

Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

Y

@CannPalAT

F

facebook.com/CannPal

Media enquiries

Julia Maguire The Capital Network M: +61 419 815 386

E: julia@thecapitalnetwork.com.au







